Five years ago, when Todd Druley, MD, PhD, was chief medical officer (CMO) for bulk sequencing diagnostics company ArcherDX, he began thinking about the next molecular diagnostics breakthrough. “We had seen the limitations of bulk sequencing and a lot of the cell-free DNA stuff,” Druley, who established his career as…

Individuals with obesity are more likely to have a benign blood condition that often precedes multiple myeloma, according to new research to be published in Blood Advances. People who are physically active, meanwhile, are less likely to have this condition, even if they are obese. Smoking and too little sleep…

In a groundbreaking collaboration, researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed the first computational model that predicts an individual’s personalized prognosis for newly diagnosed multiple myeloma. Multiple myeloma is a cancer of blood cells in the bone marrow characterized…

A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has shown that interactions between tumor genes and microenvironment influence multiple myeloma treatment response in patients newly diagnosed undergoing combination treatments, including targeted immunotherapy. The study, published in in Nature…

White patients with diabetes and multiple myeloma have lower overall survival compared to Black patients with the same illnesses, according to a study published in Blood Advances. While research has shown that patients with myeloma and diabetes have poorer survival, this is the first to show racial differences in survival…

Originally Aired: May 22, 2023Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW In this proof-of-concept study, we established a novel liquid biopsy approach, MinimuMM-seq, enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics performed on bone marrow of multiple myeloma patients. CTCs harbored the same pathognomonic…

Scientists at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have initiated a first-in-human clinical trial for patients suffering from relapsed multiple myeloma using the immunotherapy REGN5459 with a 90 percent response rate when applying high doses of the drug. Multiple myeloma is an incurable cancer of plasma…

A new test helps predict which myeloma patients will benefit most from lenalidomide (Bristol Myers Squibb’s Revlimid), which is often used to prevent relapse after a stem cell transplant. For myeloma patients with certain high-risk genetic features in their cancer cells, this drug cuts their risk of seeing their cancer…

New research led by a team from the Maine Health Institute for Research, demonstrates that fatty acid binding protein 5—FABP5—known to be involved in fat transport and metabolism aids in the progression of multiple myeloma, the second most common form of adult blood cancer. The finding, published in eLife, could…

Data from a clinical trial published in The New England Journal of Medicine (NEJM) from researchers at Memorial Sloan Kettering Cancer Center (MSKCC) indicates that people with recurrent multiple myeloma may benefit from receiving chimeric antigen receptor (CAR) T therapy earlier in the course of their cancer. The Phase III…

New evidence supports the use of a three drug combo—carfilzomib, lenolidomide, and dexamethasone (KRd), for maintenance therapy after autologous stem cell transplantation in patients newly diagnosed with multiple myeloma. Maintenance therapy using these three drugs may improve progression-free survival as compared to single agent lenalidomide treatment. After almost 34 months…

A new multi-center study has found that therapies which engage T cells such as bispecific antibodies and CAR-T cell therapies exhibit the most durable response in patients with relapsed or refractory multiple myeloma following BCMA-directed CAR-T cell therapy. The study, published in the journal Blood,  was led by Sham Mailankody, MBBS, medical…

A new computed tomography (CT) technology, first introduced to the clinic last year, has demonstrated superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a new study published in Radiology, a journal of the Radiological Society of North America (RSNA). The…

Mount Sinai researchers have for the first time identified genes that predict a good response to Selinexor, a new therapy for multiple myeloma, but one that can have serious side effects for some patients. Karyopharm’s selinexor (XPOVIO) is the first selective inhibitor of nuclear export to be approved for multiple myeloma.…

A five-drug combination therapy using existing drugs, combined with a stem cell transplant, has proven effective at extending the life of patients with an ultra-high risk form of multiple myeloma than those who received standard of care. The new research from investigators at the Institute of Cancer Research, London, and…